Market Overview:
The global cancer tubulin inhibitors market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing incidence of cancer, rising awareness about cancer treatments, and technological advancements in the field of oncology. The global cancer tubulin inhibitors market is segmented by type into docetaxel, trastuzumab emtansine, abraxane, brentuximab vedotin, and cabazitaxel. The docetaxel segment is expected to dominate the market during the forecast period owing to its high demand for treating various types of cancers such as non-small cell lung cancer (NSCLC), prostate cancer, breast cancer, colorectalcancer (CRC), and ovariancancer. Trastuzumab emtansine is also expected to witness high demand due its ability tomulti-target HER2+ tumors. On basis of application ,the globalcancer tubulin inhibitorsmarketis divided into NSCLC ,prostatecancer ,breastcancer ,colorectalcancer(CRC)and ovarian Cancer .
Product Definition:
Cancer Tubulin Inhibitors are drugs that block the formation of cancer cells by preventing the tubulin protein from assembling into microtubules. This interrupts cell division and ultimately prevents tumors from forming.
Docetaxel:
Docetaxel (Taxotere) is a taxane-based chemotherapy drug and has been approved by the U.S. FDA for treatment of breast cancer in women after HER2 amplification, who are resistant to Herceptin therapy. Docetaxel is also used as an Adjuvant Chemotherapy drug with Gemcitabine or 5-FU for the treatment of Non-Small Cell Lung Cancer (NSCLC).
Trastuzumab Emtansine:
Trastuzumab emtansine is a humanized monoclonal antibody that targets and binds to the HER-2/neu oncogene. It was developed by Roche in collaboration with Eli Lilly & Company. The drug received FDA approval for breast cancer in 2006 and 2007, and later for lung, brain, colorectal cancer as well as head & neck cancer; it is currently approved across five tumor types.
Application Insights:
Non-small cell lung cancer (NSCLC) accounted for the largest revenue share in 2017 owing to the availability of a number of products for treatment, such as cabozantinib, erlotinib, and afatinib. Moreover, ongoing research pertaining to targeted therapy is also expected to drive growth during the forecast period. For instance, Gleevec Pharmaceuticals¢â‚¬â„¢ pipeline consists of several promising drugs that are under various stages of clinical trials and are aimed at treating different types of cancers including pancreatic cancer and NSCLF.
The prostate cancer segment is expected to witness lucrative growth over the forecast period due largely on an increase in incidence rates coupled with high product penetration. In addition, key players have been conducting clinical trials for developing novel molecules specifically designed towards treating prostate cancer which is further anticipated to boost market growth during the forecast period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, such as Pfizer Inc.; Merck & Co., Inc.; and Celgene Corporation; in this region. The U.S.-based companies are engaged in extensive R&D activities for developing novel drugs with improved efficacy and reduced side effects compared to existing cancer drugs available today.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income, improving healthcare infrastructure, growing patient awareness levels coupled with increasing government initiatives for tackling cancer at its primary source thus leading to an increase in drug adoption rates which will further drive revenue generation opportunities for manufacturers operating within this region during the forecast period from 2018-2030 (Ref: Trends Journal).
Growth Factors:
- Increasing incidence of cancer across the globe is expected to drive the demand for cancer tubulin inhibitors over the forecast period.
- Rising awareness about early diagnosis and treatment of cancer is anticipated to boost the market growth.
- Technological advancements in drug development are likely to propel the market growth during the forecast period.
- Growing number of clinical trials for novel cancer tubulin inhibitors is projected to create lucrative opportunities for market players in near future .
Scope Of The Report
Report Attributes
Report Details
Report Title
Cancer Tubulin Inhibitors Market Research Report
By Type
Docetaxel, Trastuzumab Emtansine, Abraxane, Brentuximab Vedotin, Cabazitaxel
By Application
Non Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Ovarian Cancer
By Companies
Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, Genentech, Immunogen, Modra Pharmaceuticals, Pierre Fabre, Abraxis Biosciences, Sanofi-Aventis, Seattle Genetics, Tocris Bioscience
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
172
Number of Tables & Figures
121
Customization Available
Yes, the report can be customized as per your need.
Global Cancer Tubulin Inhibitors Market Report Segments:
The global Cancer Tubulin Inhibitors market is segmented on the basis of:
Types
Docetaxel, Trastuzumab Emtansine, Abraxane, Brentuximab Vedotin, Cabazitaxel
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Non Small Cell Lung Cancer, Prostate Cancer, Breast Cancer, Colorectal Cancer, Ovarian Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abraxis Biosciences
- Agensys
- Amgen
- Celgene
- Eagle Pharmaceuticals
- Endocyte
- Genentech
- Immunogen
- Modra Pharmaceuticals
- Pierre Fabre
- Abraxis Biosciences
- Sanofi-Aventis
- Seattle Genetics
- Tocris Bioscience
Highlights of The Cancer Tubulin Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Docetaxel
- Trastuzumab Emtansine
- Abraxane
- Brentuximab Vedotin
- Cabazitaxel
- By Application:
- Non Small Cell Lung Cancer
- Prostate Cancer
- Breast Cancer
- Colorectal Cancer
- Ovarian Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cancer Tubulin Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Cancer tubulin inhibitors are drugs that interfere with the growth of cancer cells. They can be used to treat a variety of cancers, including leukemia, breast cancer, and prostate cancer.
Some of the major companies in the cancer tubulin inhibitors market are Abraxis Biosciences, Agensys, Amgen, Celgene, Eagle Pharmaceuticals, Endocyte, Genentech, Immunogen, Modra Pharmaceuticals, Pierre Fabre, Abraxis Biosciences, Sanofi-Aventis, Seattle Genetics, Tocris Bioscience.
The cancer tubulin inhibitors market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cancer Tubulin Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cancer Tubulin Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cancer Tubulin Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cancer Tubulin Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cancer Tubulin Inhibitors Market Size & Forecast, 2020-2028
4.5.1 Cancer Tubulin Inhibitors Market Size and Y-o-Y Growth
4.5.2 Cancer Tubulin Inhibitors Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Docetaxel
5.2.2 Trastuzumab Emtansine
5.2.3 Abraxane
5.2.4 Brentuximab Vedotin
5.2.5 Cabazitaxel
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Non Small Cell Lung Cancer
6.2.2 Prostate Cancer
6.2.3 Breast Cancer
6.2.4 Colorectal Cancer
6.2.5 Ovarian Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cancer Tubulin Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cancer Tubulin Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Docetaxel
9.6.2 Trastuzumab Emtansine
9.6.3 Abraxane
9.6.4 Brentuximab Vedotin
9.6.5 Cabazitaxel
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Non Small Cell Lung Cancer
9.10.2 Prostate Cancer
9.10.3 Breast Cancer
9.10.4 Colorectal Cancer
9.10.5 Ovarian Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Docetaxel
10.6.2 Trastuzumab Emtansine
10.6.3 Abraxane
10.6.4 Brentuximab Vedotin
10.6.5 Cabazitaxel
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Non Small Cell Lung Cancer
10.10.2 Prostate Cancer
10.10.3 Breast Cancer
10.10.4 Colorectal Cancer
10.10.5 Ovarian Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Docetaxel
11.6.2 Trastuzumab Emtansine
11.6.3 Abraxane
11.6.4 Brentuximab Vedotin
11.6.5 Cabazitaxel
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Non Small Cell Lung Cancer
11.10.2 Prostate Cancer
11.10.3 Breast Cancer
11.10.4 Colorectal Cancer
11.10.5 Ovarian Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Docetaxel
12.6.2 Trastuzumab Emtansine
12.6.3 Abraxane
12.6.4 Brentuximab Vedotin
12.6.5 Cabazitaxel
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Non Small Cell Lung Cancer
12.10.2 Prostate Cancer
12.10.3 Breast Cancer
12.10.4 Colorectal Cancer
12.10.5 Ovarian Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Docetaxel
13.6.2 Trastuzumab Emtansine
13.6.3 Abraxane
13.6.4 Brentuximab Vedotin
13.6.5 Cabazitaxel
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Non Small Cell Lung Cancer
13.10.2 Prostate Cancer
13.10.3 Breast Cancer
13.10.4 Colorectal Cancer
13.10.5 Ovarian Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cancer Tubulin Inhibitors Market: Competitive Dashboard
14.2 Global Cancer Tubulin Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abraxis Biosciences
14.3.2 Agensys
14.3.3 Amgen
14.3.4 Celgene
14.3.5 Eagle Pharmaceuticals
14.3.6 Endocyte
14.3.7 Genentech
14.3.8 Immunogen
14.3.9 Modra Pharmaceuticals
14.3.10 Pierre Fabre
14.3.11 Abraxis Biosciences
14.3.12 Sanofi-Aventis
14.3.13 Seattle Genetics
14.3.14 Tocris Bioscience
